The YF vaccine is a live vaccine administered as a single intramuscular injection. 80%-100% individuals who receive the vaccine develop neutralizing antibodies. Although antibodies have been detected even 19 years after initial vaccine, the vaccine is expected to provide protection for 10 years, after which a repeat vaccine is required for those returning to risk areas. As the YF vaccine is a live vaccine it is relatively contraindicated in persons with immune dysfunction and infants less than 6 months of age. Antibody response is delayed in older persons and risk for adverse events also increases with age. Risks and benefits of vaccination in persons with HIV and pregnant females are discussed in detail in the CDC summary guidelines. In June 2013, the WHO published a position paper regarding vaccination against YF based on discussions by the WHO Strategic Advisory Group of Experts on Immunizations (SAGE) at its meeting in April 2013.
Look Out for Changing Recommendations Regarding the Tetanus, Diphtheria and Acellular Pertussis (Tdap) and the Yellow Fever (YF) Vaccines: A Call from Increased Tdap Vaccination and Suggestion for Decreased YF Vaccination: Alwyn Rapose
Last date updated on March, 2021